Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 | P05023 | 6/20 | 0.75 |
| ▸ | ATP1B1 | P05026 | 6/20 | 0.75 |
| ▸ | ATP1A3 | P13637 | 6/20 | 0.75 |
| ▸ | ATP1B2 | P14415 | 6/20 | 0.75 |
| ▸ | ATP1A2 | P50993 | 6/20 | 0.75 |
| ▸ | ATP1B3 | P54709 | 6/20 | 0.75 |
| ▸ | FXYD2 | P54710 | 6/20 | 0.75 |
| ▸ | ATP1A4 | Q13733 | 6/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.75 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.75 |
| ▸ | AR | P10275 | 1/20 | 0.75 |
| ▸ | ZFP91 | Q96JP5 | 1/20 | 0.75 |
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gamabufotalin SCHEMBL1484413 | 1.00 | ATP1A1 (0.75) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Gamabufotalin SCHEMBL866039 | 1.00 | ATP1A1 (0.75) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL14477877 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL21129737 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL165666 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL23382204 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL15864888 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL21083171 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL19415190 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Bufalin SCHEMBL20127236 | 0.86 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| CN-120019812-A | Artificial toad venom composition and application thereof | 南京中医药大学 | 2025-05-20 | — | — | CN | claimed |
| CN-117630225-B | Method for establishing high-efficiency liquid-phase characteristic spectrum of bear gall heart-saving pill | 山东宏济堂制药集团股份有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119395166-A | Separation method of chemical components of toad skin extract and preparation thereof or construction method and quality control method of fingerprint | 安徽华润金蟾药业有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-118987048-A | A method for preparing Bufonis venenum extract with low irritation | 中国标准化研究院 | 2024-11-22 | — | — | CN | claimed |
| CN-119000938-A | Quality detection method and fingerprint construction method for dried toad skin extract | 上海中医药大学附属龙华医院 | 2024-11-22 | — | — | CN | claimed |
| CN-115990136-B | Antitumor composition, nano preparation, preparation method and application | 中南大学湘雅三医院 | 2024-09-03 | — | — | CN | claimed |
| CN-117771253-A | Pharmaceutical composition for resisting colorectal cancer and application thereof | 遵义医科大学 | 2024-03-29 | — | — | CN | claimed |
| CN-117695403-A | 'fungus-medicine' nano composite system and its preparation method and application | 湖南大学 | 2024-03-15 | — | — | CN | claimed |
| CN-117630225-A | Method for establishing high-efficiency liquid-phase characteristic spectrum of bear gall heart-saving pill | 山东宏济堂制药集团股份有限公司 | 2024-03-01 | — | — | CN | claimed |
| CN-102688248-B | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | UNIV NANJING CHINESE MEDICINE | 2014-08-27 | — | — | CN | claimed |
| CN-103156870-A | Pharmaceutical composition for treating cardiovascular disease and preparation method thereof | SHANGHAI HUTCHISON PHARMACEUTICALS CO LTD | 2013-06-19 | — | — | CN | claimed |
| CN-102688248-A | Use of bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors | UNIV NANJING CHINESE MEDICINE | 2012-09-26 | — | — | CN | claimed |
| CN-102526111-A | Slow-release microsphere containing venenum bufonis lipoclastic substances as well as preparation method and application thereof | UNIV SOUTH CHINA AGRICULT | 2012-07-04 | — | — | CN | claimed |
| CN-102486472-A | Method for determining medicine active component in serum | SHANGHAI HUTCHISON PHARMACEUTICALS CO LTD | 2012-06-06 | — | — | CN | claimed |
| US-20110076278-A1 | Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders | BIONAUT PHARMACEUTICALS INC | 2011-03-31 | — | — | US | claimed |
| CN-101485666-B | Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor | UNIV NANJING CHINESE MEDICINE | 2010-12-29 | — | — | CN | claimed |
| CN-101485666-A | Application of Gamabufotalin and salt thereof in preparing medicament for treating gynaecologic tumor | UNIV NANJING TRAD CHINESE MED (CN) | 2009-07-22 | — | — | CN | claimed |
| EP-1928470-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS | Bionaut Pharmaceuticals (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007016656-A2 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES FOR THE TREATMENT OF OCULAR DISORDERS | BTG INTERNATIONAL LIMITED (GB) | 2007-02-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110076278-A1 | Modulators of Hypoxia Inducible Factor-1 and Related Uses for the Treatment of Ocular Disorders | HIF1A, HIF1AN, HYOU1 | ATP1A1 307/4885ATP1B1 102/4885ATP1A3 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.